Following development by the GM NMP Leads Group and review by the GM Workforce Group, we now seek comments on the draft document: ‘Greater Manchester Non-Medical Prescribing Best Practice Guide’.
The consultation will run for six weeks and closes at 5pm on Thursday 2nd November 2023. To take part, visit the consultations page.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.
Following development by a clinical working group and review by CRG, we now seek comments on the draft update of the GMMMG High Cost Drugs Inflammatory Bowel Disease Pathway.
The consultation will run for 6 weeks, closing at 5pm on 30th August. To take part, please visit the consultations page.
Following development by Wigan Borough locality and adaptation by the GM Medicines Safety Group, we now seek comments on the draft document: ‘Safe Management of Medicines within GP Practices, An Example of Good Practice’.
The consultation will run for 6 weeks, closing at 5pm on 30th August. To take part, please visit the consultations page.
The Greater Manchester Clinical Reference Group reviewed a request to add omalizumab to formulary for the unlicensed indications of severe chronic inducible urticarias (solar urticaria, cold and heat urticaria, symptomatic dermographism, delayed pressure urticaria and cholinergic urticaria). We now seek comments on this draft
The consultation will run for 6 weeks, closing at 5pm on 29th August. To take part, please visit the consultations page.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their July 2023 meeting. Actions in this consultation include:
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Tuesday 29th August 2023. To take part, visit the consultations page.
The Greater Manchester Medicines Value Subgroup have drafted a Greater Manchester High-Cost Drugs Commissioning Pathway for Wet Age-related Macular Degeneration in Adults and now seek comments on the draft.
Please note the download is a zipped folder containing two documents:
The consultation will run for 6 weeks, closing at 5pm on Monday 21st August. To take part, please visit the consultations page.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their June 2023 meeting. Actions in this consultation include:
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 28th July 2023.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their May 2023 meeting. Actions in this consultation include:
All links to MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 23rd June 2023.